Reuters logo
BRIEF-Gilead receives approval in Canada for expanded indication of epclusa
2017年9月21日 / 上午10点54分 / 1 个月内

BRIEF-Gilead receives approval in Canada for expanded indication of epclusa

Sept 21 (Reuters) - Gilead Sciences Inc:

* Gilead receives approval in Canada for expanded indication of epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV

* Gilead Sciences Inc - ‍safety profile of epclusa in hcv/hiv co-infected patients was similar to that observed in hcv mono-infected patients​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below